ESC Premium Access

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Congress Presentation

About the speaker

Associate Professor Thomas A Zelniker

Medical University of Vienna, Vienna (Austria)
0 follower

4 more presentations in this session

State of the Art - SGLT2 inhibitors in cardiovascular disease

Speaker: Professor M. Sabatine (Boston, US)


Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

Speaker: Doctor J. Udell (Toronto, CA)


SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

Speaker: Doctor C. Noergaard (Aalborg, DK)


Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists

Speaker: Professor N. Sattar (Glasgow, GB)


Access the full session

New frontiers: SGLT2 inhibitors in cardiorenal disease

Speakers: Associate Professor T. Zelniker, Professor M. Sabatine, Doctor J. Udell, Doctor C. Noergaard, Professor N. Sattar

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by